Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > Stats for the upcoming financials
View:
Post by donmayne on Mar 07, 2022 1:35pm

Stats for the upcoming financials

Quartery Scorecard

Company Guidance (announced Nov 1, 2021 with Q3 results)


"The Company expects to generate net revenues attributable to its core business of approximately $27.8 million to $28.8 million during the fourth quarter of 2021. While the Company's COVID-19 response related business has slowed during the current year, the Company is continuing to pursue additional sales and support revenues and estimates fourth quarter 2021 net revenues of approximately $1.5 million to $1.7 million related to the COVID-19 pandemic. Total net revenues for the fourth quarter of 2021 are estimated to be approximately $29.3 million to $30.5 million."
  • Q3 2021 stats
  • Total Revenue: 29,3
  • Core Business revenue: 27.8
  •    Vent revenue: 21.3
  •    Other core revenue: 6.5
  • Covid related revenue: 1.5
  • Net Income: 1.8
  • Adjusted Ebita: 7.4
  • Cash balance: 26.9
  • Vent patients 8200 
 
  • Q4 2020 Stats
  • Total Revenue: 31.2
  • Core Business revenue: 26.1
  •    Vent Revenue: 20.6
  •    Other core revenue: 5.5
  • Covid related revenue: 5.1
  • Net Income: 5.1
  • Adjusted Ebita: 9.5
  • Cash balance: 31.0
  • Vent patients 7892
I will be looking for the growth in core business revenue and increase in vent patients.  It should give us a window of what to expect in terms of growth for the balance of the 2022 year.  One must factor out the last two weeks of Q4 2021 and the first six weeks of Q1 2022 when the Omicron wave overwhelmed hosptials.

I will be looking for longer term guidance for 2022 and, because of Omicron, not just Q1 2022.
Comment by Trytobelong on Mar 07, 2022 4:24pm
and all those numbers are in US
Comment by donmayne on Mar 07, 2022 5:29pm
The results are in for Q4.  They reported core business revenues of 29.0 which beat the high end of their guidance range 27.8-28.8.  This is good news. The total net revenues of 32.0 also beat the high end of their guidance range of $29.3-30.5.  This is good news. Their net income per share at 0.10 beat of the analyst estimate range of 0.05-0.09.  This is good news. Vent ...more  
Comment by LongTerm3 on Mar 07, 2022 5:32pm
Adjusted Ebita of $9,549 Million for the quarter. $29,283 million for the year    Liabilities are down,  Cash is up!   They beat on every number.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities